- Quintiles Transnational of the USA has signed an agreement with the Israeli contract research organization Mor-Research Applications, to collaborate on drug development clinical trials and research projects for industry clients. Under the terms of the agreement, Quintile will gain access to the patients and investigators affiliated with Mor's parent company, Kupat Holim, and Mor will be provided with training in clinical practice and other aspects of contract-research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze